(Corrects headline to say “IBD”, not “IBS”)
April 3 (Reuters) - Palatin Technologies Inc:
* PALATIN TECHNOLOGIES PRESENTS PRECLINICAL ORAL FORMULATION DATA ON PL-8177, AN INVESTIGATIONAL MELANOCORTIN RECEPTOR 1 AGONIST FOR INFLAMMATORY BOWEL DISEASES
* PALATIN TECHNOLOGIES INC - SUBJECT DOSING IS ONGOING WITH TOP LINE DATA CURRENTLY EXPECTED IN Q3 OF 2018 FOR PL-8177 Source text for Eikon: Further company coverage: